Telesis Bio, Inc. · OTC:TBIO
Telesis Bio — Investor Presentation (January 2026)
15 slides from Telesis Bio's investor presentation, January 2026
Slide 1: Corporate Overview
Corporate Overview Telesis Bio | Q1 2026
Slide 2: Safe Harbor Statement
Safe Harbor Statement The information contained in this presentation has been made available to you with the consent of Telesis Bio Inc. (“Telesis Bio,” the “Company,” “we” or “our”) for informational purposes only. This presentation is strictly confidential and may not be reproduced or redistribute
Slide 3: Unlocking the power of on-demand biology to transform therapeutic development
Unlocking the power of on-demand biology to transform therapeutic development Gibson SOLA for overnight synthetic biology
Slide 4: Leadership Team of Domain Experts
Leadership Team of Domain Experts Eric Esser Rocky McDonald Daniel Gibson Krishna Kannan President & CEO Senior VP, Finance Chief Technology Officer VP, Product and Operations ©2026 Telesis Bio 4
Slide 5: Telesis Bio Is Built on a History of Innovation in Molecular Biology
Telesis Bio Is Built on a History of Innovation in Molecular Biology 330+ patents in Telesis patent portfolio Original IP Digital to Biological Gibson Short Oligonucleotide from JCVI Conversion Ligation Assembly (SOLA) Gibson Assembly Telesis Bio Established Digital to biological converter ©2026 Tel
Slide 6: Distributed Synthesis Eliminates Constraints on Therapeutic Discovery and Development
Distributed Synthesis Eliminates Constraints on Therapeutic Discovery and Development Shrink Timelines Control Quality No more waiting for Stop worrying about variable external supply, iterate purity and fidelity way faster Break Free from Limits Control Your IP Gain the freedom to explore Keep your
Slide 7: Gibson SOLA On-Demand Synthesis Supercharges Productivity
Gibson SOLA On-Demand Synthesis Supercharges Productivity Comprehensive and flexible reagent and software solution for in-lab synthesis to accelerate discovery DNA Synthesis • Unlock the power of overnight synthesis of DNA, mRNA and protein • Extreme quality, high reliability, and fully Cloning Gene
Slide 8: Our Gibson SOLA Reagent and Software Platform
Our Gibson SOLA Reagent and Software Platform Reagent Kits Simple and flexible chemistry for synthesis Block approach Assembly Easy to scale with standard liquid handling automation Amenable to very high throughput applications Advanced Software Simple, reliable, and fast ligation approach enables v
Slide 9: Gibson SOLA is a Scalable Fully Enzymatic Process
Gibson SOLA is a Scalable Fully Enzymatic Process Fixed building blocks and four reaction steps reliably produce extremely high-fidelity DNA Pooling 100-mer subunit assembly Gene build Stocked Source Plates Digestion & hybridization of Pool 100-mers building blocks Digest Ligate Intelligent Synthesi
Slide 10: How we're delivering Gibson SOLA to the market
How we’re delivering Gibson SOLA to the market Gibson SOLA Discovery Gibson SOLA Clinical SOLA-Enabled Gibson SOLA Gibson SOLA BioXp Beckman Integrated Selected by 4 Applicants Accelerated, High-throughput > 100kb/day, SOLA-quality (~30kb/day), turnkey integrated, custom Future Development License a
Slide 11: Commercial deliveries of Gibson SOLA Discovery Underway
Commercial deliveries of Gibson SOLA Discovery Underway Building enthusiasm and making good progress in the early innings Gibson SOLA Discovery in 2025 • Commercially ready • Fully automated and running at Telesis Bio • Six licensees across three Gibson SOLA Discovery categories • Strong pipeline co
Slide 12: Gibson SOLA Clinical Enables Precision Therapeutics
Gibson SOLA Clinical Enables Precision Therapeutics Personalized therapies require fast and distributed manufacturing of patient-specific drugs Individualized Distributed synthesis Gibson SOLA is ideal First mover owns the therapeutics are is required, the for distributed “last mile” to the coming p
Slide 13: SOLA is the best platform for integrated on-demand synthesis
SOLA is the best platform for integrated on-demand synthesis Simple enzymatic process makes miniaturization feasible DL-3 PCR-4 DL-4 PCR-5 Collapse Collapse products products for further for further processing processing High-fidelity synthesis Finite, reusable parts library Built-in error suppressi
Slide 14: Innovating Solutions to Rapidly Advance Therapeutic and Diagnostic Development
Innovating Solutions to Rapidly Advance Therapeutic and Diagnostic Development Gibson SOLA - Groundbreaking next-gen technology Meeting market needs – Experienced team with overnight results, market expertise complexity, control Targeting high value Nimble company focused applications on efficiency
Slide 15: Thank You
Thank You CONTACT Rocky McDonald, Senior VP of Finance Rocky.McDonald@telesisbio.com (619) 518-9270 16